Why the study?
Despite the high antiviral potency of baloxavir marboxil, drug-resistant influenza variants have been observed in clinical trials.
Answers are grounded in this paper and cite their sources.
A novel macrocyclic CEN inhibitor shows promise in overcoming baloxavir resistance in influenza viruses.
Influenza viruses (IFVs) have caused several pandemics and have claimed numerous lives since their first record in the early 20th century. While the outbreak of COVID-19 seemed to expel influenza from the sight of people for a short period of time, it is not surprising that it will recirculate around the globe after the coronavirus has mutated into a less fatal variant. Baloxavir marboxil ( 1 ), the prodrug of baloxavir ( 2 ) and a cap-dependent endonuclease (CEN) inhibitor, were approved by the FDA for the first treatment in almost 20 years. Despite their high antiviral potency, drug-resistant variants have been observed in clinical trials. Herein, we report a novel CEN inhibitor 8 with a delicately designed macrocyclic scaffold that exhibits a significantly smaller shift of inhibitory activity toward baloxavir-resistant variants.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: